Related Experiment Video
Updated: Jul 28, 2026
Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
[Experience in clinical use of primalan (mequitazine) in allergology]
Aim:
To study efficacy of primalan (mequitasine) in the treatment of allergic rhinoconjunctivitis and chronic recurrent urticaria.
Material And Methods:
The study included 140 patients. Of them, 60 patients had allergic rhinitis, 80 patients had chronic recurrent urticaria. All the patients received primalan (mequitasin) in a dose 10 mg/day (5 mg twice daily or a single dose 10 mg). The disease symptoms and side effects of primalan were assessed for 28 days of the treatment.
Results:
Primalan (mequitasin) proved to be highly effective against allergic rhinitis (good and very good response--76%, satisfactory--20%) and chronic recurrent urticaria (the response in 90% patients). Good primalan tolerance was reported. Side effects were moderate and did not require the drug withdrawal (sleepiness in 6.6%, dryness of the mucosa in 5%).
Conclusion:
Primalan (mequitasin) can be recommended for wide application in therapy of allergic rhinitis and chronic recurrent urticaria.
Related Concept Videos
02:06Allergic Reactions
01:24Cholinergic Antagonists: Pharmacokinetics
01:23Local Anesthetics: Common Agents and Their Applications
Cocaine is an ester of benzoic acid and methylecgogine. It is used to anesthetize and vasoconstrict locally. Currently, it is used primarily for topical applications. It is beneficial for surgeries on the upper respiratory tract, providing anesthesia and shrinking the mucosa. Cocaine in the form of cocaine hydrochloride is...